Twist Bioscience Co. (NASDAQ:TWST) Receives $48.22 Average PT from Analysts

Twist Bioscience Co. (NASDAQ:TWST) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $48.22.

A number of research analysts have recently commented on the stock. TD Cowen increased their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, The Goldman Sachs Group raised their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th.

Twist Bioscience Stock Up 8.9 %

Shares of Twist Bioscience stock opened at $44.36 on Thursday. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -13.20 and a beta of 1.76. Twist Bioscience has a 12-month low of $14.42 and a 12-month high of $60.90. The firm’s 50-day moving average price is $47.85 and its two-hundred day moving average price is $42.67.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s revenue was up 27.7% compared to the same quarter last year. During the same period last year, the company posted ($1.01) EPS. On average, sell-side analysts expect that Twist Bioscience will post -3.13 earnings per share for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares in the company, valued at approximately $3,154,310.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares in the company, valued at approximately $3,154,310.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,732 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total transaction of $85,578.12. Following the sale, the chief executive officer now directly owns 505,846 shares of the company’s stock, valued at approximately $24,993,850.86. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,483 shares of company stock worth $781,448. 3.92% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

Large investors have recently modified their holdings of the stock. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $30,000. Blue Trust Inc. grew its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $61,000. Nisa Investment Advisors LLC grew its position in shares of Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC grew its position in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.